Top

Published in:

Open Access 01-12-2011 | Review

The rising problem of antimicrobial resistance in the intensive care unit

Authors: Nele Brusselaers, Dirk Vogelaers, Stijn Blot

Published in: Annals of Intensive Care | Issue 1/2011

Abstract

Mainly due to its extremely vulnerable population of critically ill patients, and the high use of (invasive) procedures, the intensive care unit (ICU) is the epicenter of infections. These infections are associated with an important rise in morbidity, mortality, and healthcare costs. The additional problem of multidrug-resistant pathogens boosts the adverse impact of infections in ICUs. Several factors influence the rapid spread of multidrug-resistant pathogens in the ICU, e.g., new mutations, selection of resistant strains, and suboptimal infection control. Among gram-positive organisms, the most important resistant microorganisms in the ICU are currently methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. In gram-negative bacteria, the resistance is mainly due to the rapid increase of extended-spectrum Beta-lactamases (ESBLs) in Klebsiella pneumonia, Escherichia coli, and Proteus species and high level third-generation cephalosporin Beta-lactamase resistance among Enterobacter spp. and Citrobacter spp., and multidrug resistance in Pseudomonas aeruginosa and Acinetobacter species. To conclude, additional efforts are needed in the future to slow down the emergence of antimicrobial resistance. Constant evaluation of current practice on basis of trends in MDR and antibiotic consumption patterns is essential to make progress in this problematic matter.

Marwick C, Davey P: Care bundles: the holy grail of infectious risk management in hospital? Curr Opin Infect Dis 2009, 22: 364–369. 10.1097/QCO.0b013e32832e0736PubMedCrossRef

Hanberger H, Garcia-Rodriguez JA, Gobernado M, Goossens H, Nilsson LE, Struelens MJ: Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. JAMA 1999, 281: 67–71. 10.1001/jama.281.1.67PubMedCrossRef

Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, Wolff M, Spencer RC, Hemmer M: The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995, 274: 639–644. 10.1001/jama.274.8.639PubMedCrossRef

Vandijck DM, Depaemelaere M, Labeau SO, Depuydt PO, Annemans L, Buyle FM, Oeyen S, Colpaert KE, Peleman RP, Blot SI, Decruyenaere JM: Daily cost of antimicrobial therapy in patients with Intensive Care Unit-acquired, laboratory-confirmed bloodstream infection. Int J Antimicrob Agents 2008, 31: 161–165. 10.1016/j.ijantimicag.2007.10.015PubMedCrossRef

Blot S: Limiting the attributable mortality of nosocomial infection and multidrug resistance in intensive care units. Clin Microbiol Infect 2008, 14: 5–13.PubMedCrossRef

Blot S, Depuydt P, Vandewoude K, De Bacquer D: Measuring the impact of multidrug resistance in nosocomial infection. Curr Opin Infect Dis 2007, 20: 391–396. 10.1097/QCO.0b013e32818be6f7PubMedCrossRef

Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K: International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302: 2323–2329. 10.1001/jama.2009.1754PubMedCrossRef

Carlet J, Ben Ali A, Tabah A, Willems V, Philippart F, Chafine A, Garrouste-Orgeas M, Misset B: Multidrug resistant infections in the ICU: mechanisms, prevention and treatment. In 25 Years of Progress and Innovation in Intensive Care Medicine. Edited by: Kuhlen R, Moreno R, Ranieri VM, Rhodes A. Berlin, Germany: Medizinisch Wissenschaftliche Verlagsgesellschaft; 2007:199–211.

Salgado CD, O'Grady N, Farr BM: Prevention and control of antimicrobial-resistant infections in intensive care patients. Crit Care Med 2005, 33: 2373–2382. 10.1097/01.CCM.0000181727.04501.F3PubMedCrossRef

10.

Cosgrove SE: The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006,42(Suppl 2):S82-S89.PubMedCrossRef

11.

Figueiredo Costa S: Impact of antimicrobial resistance on the treatment and outcome of patients with sepsis. Shock 2008,30(Suppl 1):23–29. 10.1097/SHK.0b013e3181818990PubMedCrossRef

12.

de Kraker ME, Wolkewitz M, Davey PG, Grundmann H: Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother 2011, 55: 1598–1605. 10.1128/AAC.01157-10PubMedCentralPubMedCrossRef

13.

de Kraker ME, Wolkewitz M, Davey PG, Koller W, Berger J, Nagler J, Icket C, Kalenic S, Horvatic J, Seifert H, et al.: Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother 2011, 66: 398–407. 10.1093/jac/dkq412PubMedCrossRef

14.

Borg MA: Bed occupancy and overcrowding as determinant factors in the incidence of MRSA infections within general ward settings. J Hosp Infect 2003, 54: 316–318. 10.1016/S0195-6701(03)00153-1PubMedCrossRef

15.

Clark NM, Hershberger E, Zervosc MJ, Lynch JP: Antimicrobial resistance among gram-positive organisms in the intensive care unit. Curr Opin Crit Care 2003, 9: 403–412. 10.1097/00075198-200310000-00011PubMedCrossRef

16.

Bonten MJ, Mascini EM: The hidden faces of the epidemiology of antibiotic resistance. Intensive Care Med 2003, 29: 1–2.PubMedCrossRef

17.

Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J: Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48: 1–12. 10.1086/595011PubMedCrossRef

18.

Jones RN: Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 2001, 119: 397S-404S. 10.1378/chest.119.2_suppl.397SPubMedCrossRef

19.

National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992-June 2001, issued August 2001 Am J Infect Control 2001, 29: 404–421.

20.

Arias CA, Contreras GA, Murray BE: Management of multidrug-resistant enterococcal infections. Clin Microb Infect 2010, 16: 555–562. 10.1111/j.1469-0691.2010.03214.xCrossRef

21.

Clark NM, Patterson J, Lynch JP: Antimicrobial resistance among gram-negative organisms in the intensive care unit. Curr Opin Crit Care 2003, 9: 413–423. 10.1097/00075198-200310000-00012PubMedCrossRef

22.

Paterson DL: The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006,43(Suppl 2):S43–48.PubMedCrossRef

23.

Goossens H, Grabein B: Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997–2004). Diagn Microbiol Infect Dis 2005, 53: 257–264. 10.1016/j.diagmicrobio.2005.10.001PubMedCrossRef

24.

Paterson DL, Bonomo RA: Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005, 18: 657–686. 10.1128/CMR.18.4.657-686.2005PubMedCentralPubMedCrossRef

25.

Pitout JD: Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 2010, 70: 313–333. 10.2165/11533040-000000000-00000PubMedCrossRef

26.

Cuzon G, Naas T, Nordmann P: [KPC carbapenemases: what is at stake in clinical microbiology?]. Pathologie-biologie 2010, 58: 39–45. 10.1016/j.patbio.2009.07.026PubMedCrossRef

27.

Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Hsueh PR, Paterson DL: Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. Antimicrob Agents Chemother 2009, 53: 3280–3284. 10.1128/AAC.00426-09PubMedCentralPubMedCrossRef

28.

Brusselaers N, Monstrey S, Snoeij T, Vandijck D, Lizy C, Hoste E, Lauwaert S, Colpaert K, Vandekerckhove L, Vogelaers D, Blot S: Morbidity and mortality of bloodstream infections in patients with severe burn injury. Am J Crit Care 2010, 19: e81–87. 10.4037/ajcc2010341PubMedCrossRef

29.

Jones RN: Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997–2001). Sem Respir Crit Care Med 2003, 24: 121–134. 10.1055/s-2003-37923CrossRef

30.

Mahgoub S, Ahmed J, Glatt AE: Completely resistant Acinetobacter baumannii strains. Infection Control Hosp Epidemiol 2002, 23: 477–479. 10.1086/502091CrossRef

31.

Kincaid SE: Clostridium difficile-associated disease: impact of the updated SHEA/IDSA guidelines. Consult Pharm 2010, 25: 834–836. 10.4140/TCP.n.2010.834PubMedCrossRef

32.

Barbut F, Petit JC: Epidemiology of Clostridium difficile-associated infections. Clin Microbiol Infect 2001, 7: 405–410. 10.1046/j.1198-743x.2001.00289.xPubMedCrossRef

33.

Shah D, Dang MD, Hasbun R, Koo HL, Jiang ZD, DuPont HL, Garey KW: Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther 2010, 8: 555–564. 10.1586/eri.10.28PubMedCentralPubMedCrossRef

34.

Brusselaers N, Blot S, Vogelaers D: Non-blood Candida infections in the ICU. Neth J Crit Care 2011, in press.

35.

Miceli MH, Diaz JA, Lee SA: Emerging opportunistic yeast infections. Lancet Infect Dis 2011, 11: 142–151. 10.1016/S1473-3099(10)70218-8PubMedCrossRef

36.

Chow JK, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg D, Chawla V, Young J, Hadley S: Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis 2008, 46: 1206–1213. 10.1086/529435PubMedCrossRef

37.

Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, Carlet J, Reynes J, Rosenheim M, Regnier B, Lortholary O: Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006). Crit Care Med 2009, 37: 1612–1618. 10.1097/CCM.0b013e31819efac0PubMedCrossRef

38.

Leroy O, Mira JP, Montravers P, Gangneux JP, Lortholary O: Comparison of albicans vs. non-albicans candidemia in French intensive care units. Crit Care 2010, 14: R98. 10.1186/cc9033PubMedCentralPubMedCrossRef

39.

Holley A, Dulhunty J, Blot S, Lipman J, Lobo S, Dancer C, Rello J, Dimopoulos G: Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. Int J Antimicrob Agents 2009.

40.

Annual epidemiological report on communicable diseases in Europe 2008: Report on the state of communicable diseases in the EU and EEA/EFTA countries In Book Annual epidemiological report on communicable diseases in Europe 2008: Report on the state of communicable diseases in the EU and EEA/EFTA countries. European Centre for Disease Prevention and Control; 2008.

41.

Vogelaers D, De Bels D, Foret F, Cran S, Gilbert E, Schoonheydt K, Blot S: Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates--a multicentre, observational survey in critically ill patients. Int J Antimicrob Agents 2010, 35: 375–381. 10.1016/j.ijantimicag.2009.11.015PubMedCrossRef

42.

Allerberger F, Gareis R, Jindrak V, Struelens MJ: Antibiotic stewardship implementation in the EU: the way forward. Expert Rev Anti Infect Ther 2009, 7: 1175–1183. 10.1586/eri.09.96PubMedCrossRef

43.

Bal AM, Gould IM: Antibiotic stewardship: overcoming implementation barriers. Curr Opin Infect Dis 2011, 24: 357–362. 10.1097/QCO.0b013e3283483262PubMedCrossRef

44.

Prowle JR, Heenen S, Singer M: Infection in the critically ill--questions we should be asking. J Antimicrob Chemother 2011,66(Suppl 2):ii3–10.PubMed

45.

Prowle JR, Echeverri JE, Ligabo EV, Sherry N, Taori GC, Crozier TM, Hart GK, Korman TM, Mayall BC, Johnson PD, Bellomo R: Acquired bloodstream infection in the intensive care unit: incidence and attributable mortality. Critical Care 2011, 15: R100. 10.1186/cc10114PubMedCentralPubMedCrossRef

46.

Lipsitch M, Bergstrom CT, Levin BR: The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. Proc Natl Acad Sci USA 2000, 97: 1938–1943. 10.1073/pnas.97.4.1938PubMedCentralPubMedCrossRef

47.

Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, et al.: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34: 1589–1596. 10.1097/01.CCM.0000217961.75225.E9PubMedCrossRef

48.

Blot S, Depuydt P, Vogelaers D: Maximizing rates of empiric appropriate antibiotic therapy with minimized use of broad-spectrum agents: are surveillance cultures the key? Intens Care Med 2008, 34: 2130–2133. 10.1007/s00134-008-1249-7CrossRef

49.

Silvestri L, Taylor N, Zandstra DF, van Saene HK: Selective digestive decontamination is superior to selective oropharyngeal decontamination. Crit Care 2011, 15: 411. 10.1186/cc10068PubMedCentralPubMedCrossRef

50.

Silvestri L, Petros AJ, De La Cal MA, Visintin S: Selective digestive decontamination. Why are intensivists more "resistant" than microorganisms? Minerva Anestesiol 2011, 77: 658–659.PubMed

51.

Zandstra DF, Van Saene HK: Selective decontamination of the digestive tract as infection prevention in the critically ill. A level 1 evidence-based strategy. Minerva Anestesiol 2011, 77: 212–219.PubMed

52.

Labeau SO, Van de Vyver K, Brusselaers N, Vogelaers D, Blot SI: Prevention of ventilator-associated pneumonia with oral antiseptics: a systematic review and meta-analysis. Lancet Infect Dis 2011.

53.

van Essen EH, de Jonge E: Selective decontamination of the digestive tract (SDD): is the game worth the candle? Sem Respir Crit Care Med 2011, 32: 236–242. 10.1055/s-0031-1275536CrossRef

54.

Struelens MJ: Multidisciplinary antimicrobial management teams: the way forward to control antimicrobial resistance in hospitals. Curr Opin Infect Dis 2003, 16: 305–307. 10.1097/00001432-200308000-00001PubMedCrossRef

55.

Vogelaers D, Blot S, Vandijck D: Infectious disease specialist consultation in the intensive care unit: worth the money? ICU Manag 2010, 10: 16–19.

56.

Raineri E, Pan A, Mondello P, Acquarolo A, Candiani A, Crema L: Role of the infectious diseases specialist consultant on the appropriateness of antimicrobial therapy prescription in an intensive care unit. Am J Infect Control 2008, 36: 283–290. 10.1016/j.ajic.2007.06.009PubMedCrossRef

Title: The rising problem of antimicrobial resistance in the intensive care unit
Authors: Nele Brusselaers
Dirk Vogelaers
Stijn Blot
Publication date: 01-12-2011
Publisher: Springer Paris
Published in: Annals of Intensive Care / Issue 1/2011
Electronic ISSN: 2110-5820
DOI: https://doi.org/10.1186/2110-5820-1-47

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The rising problem of antimicrobial resistance in the intensive care unit

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Septic cardiomyopathy

Pharmacological treatment of delayed cerebral ischemia and vasospasm in subarachnoid hemorrhage

Fluid management in acute lung injury and ards

Stress-related cardiomyopathies

Noninvasive positive pressure ventilation for acute respiratory failure in children: a concise review

Mitochondrial dysfunction and biogenesis: do ICU patients die from mitochondrial failure?